Unveiling the Concealed Correlation: The Significance of NPM1 Mutation Beyond Blast Percentage in Myeloid Neoplasms

References

[1] Gener-RicosG, BatallerA, Rodriguez-SevillaJJ, et al.. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer., 2024, 130(20): 3452-3462.

[2] DöhnerH, EsteyE, GrimwadeD, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood., 2017, 129(4): 424-447.

[3] ArberDA, OraziA, HasserjianR, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood., 2016, 127(20): 2391-2405.

[4] DiNardoCD, JonasBA, PullarkatV, et al.. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med., 2020, 383(7): 617-629.

[5] EfthimiouO, SeoM, ChalkouK, et al.. Developing clinical prediction models: a step-by-step guide. Bmj., 2024, 386. e078276

[6] PapaemmanuilE, GerstungM, BullingerL, et al.. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med., 2016, 374(23): 2209-2221.

[7] DöhnerH, WeiAH, AppelbaumFR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood., 2022, 140(12): 1345-1377.

[8] WangXQD, FanD, HanQ, et al.. Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia. Cancer Discov., 2023, 13(3): 724-745.

[9] LaiQ, HamamotoK, LuoH, et al.. NPM1 mutation reprograms leukemic transcription network via reshaping TAD topology. Leukemia., 2023, 37(8): 1732-1736.

[10] YaoY, LinX, WangC, et al.. Identification of a novel NPM1 mutation in acute myeloid leukemia. Exp Hematol Oncol., 2023, 12187.

[11] KantarjianHM, DiNardoCD, KadiaTM, et al.. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin., 2025, 75(1): 46-67.

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology